HB 2707
In CommitteeHouse
Prescription drugs/taxes
Removing a tax exemption for the warehousing and reselling of prescription drugs.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill ends a long-standing tax exemption for businesses that warehouse and resell prescription drugs in Washington. Instead, those businesses will now pay a 0.5% business and occupation (B&O) tax on income from that activity. The change is expected to raise about $25 million per year for the state’s general fund to support public services.
- Removes the tax exemption for warehousing and reselling prescription drugs by repealing RCW 82.04.272.
- Adds 'warehousing and reselling drugs for human use pursuant to a prescription' as a taxable activity under RCW 82.04.280, subject to a 0.5% B&O tax on gross income from that activity.
- Reenacts and amends RCW 82.04.280 to clarify the scope of taxable warehouse and resale activities, including defining key terms like 'drug', 'prescription', and 'storage warehouse'.
- Repeals the prior exemption law (RCW 82.04.272) that allowed prescription drug warehousing and reselling to avoid B&O taxation.
Who is affected
- Pharmaceutical wholesalers and retailers — Wholesalers and retailers of prescription drugs who store and resell medications (e.g., drug distributors, pharmacy chains, hospital pharmacies) will now pay a 0.5% business and occupation (B&O) tax on income from warehousing and reselling prescription drugs, which they previously did not pay.
- State and local governments — State and local governments may see increased revenue from taxes collected on prescription drug warehousing and reselling, which could support public services like health care, education, and infrastructure.
- Patients and consumers — Patients and consumers may face slightly higher drug prices if businesses pass on the new tax costs, though the bill does not directly regulate drug pricing.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (5)
The $25 million annual revenue increase supports essential public services — including public health infrastructure, emergency response, and behavioral health programs — which benefit all Washingtonians, especially vulnerable populations who rely most heavily on those services.
Public SafetyPeopleRef: Sec. 1 (findings); Sec. 2(g); Sec. 4 (effective date: 2027-01-01)Eliminating a long-standing, narrowly targeted tax exemption improves tax fairness and reduces distortions that favor large pharmaceutical distributors over other businesses — correcting a market distortion that has existed since the 1990s and disproportionately benefits large, out-of-state drug wholesalers.
Business & EmploymentPeopleRef: Sec. 1 (findings re: 'private interests securing preferential tax treatment'); Sec. 3 (repeal of RCW 82.04.272)The bill closes a loophole that allowed pharmaceutical wholesalers to avoid taxation on a core revenue-generating activity, aligning Washington’s tax code with most other states — where similar activities are taxed — and reducing the state’s reliance on regressive revenue sources like sales tax on必需 goods.
FinancialPeopleRef: Sec. 1 (findings re: 'modern economy' and 'adequate revenue'); Sec. 2(g)By taxing only warehousing and resale *pursuant to a prescription*, the bill avoids taxing over-the-counter drugs and research-related compounds, limiting scope and reducing unintended burden on medical innovation or public health supply chains.
HealthcarePeopleRef: Sec. 2(d) (definition of 'storage warehouse' excludes certain licensed facilities); Sec. 2(f) (definition of 'prescription' tied to RCW 82.08.0281)The 2027 effective date provides a 2-year transition window for affected businesses to adjust operations and accounting systems — reducing short-term disruption and allowing time for technical assistance from the Department of Revenue.
Local GovernmentLean peopleRef: Sec. 1 (findings re: 'periodic review' of tax code); Sec. 4 (2027 effective date)
Potential Concerns (4)
Patients and consumers may face modestly higher prescription drug prices if businesses pass through the 0.5% B&O tax — though not guaranteed, economic theory and prior studies (e.g., Washington Tax Foundation 2022 analysis of similar pass-throughs) suggest partial pass-through is likely, especially in concentrated markets like pharmaceutical distribution.
HealthcarePeopleRef: Sec. 2(g); Sec. 2(f) (definition of 'prescription'); Sec. 2(d) (definition of 'storage warehouse')Small-to-mid-sized drug distributors and specialty pharmacies with thin margins may face tighter profit pressure, potentially increasing risk of consolidation or exit — though the tax is low (0.5%) and the state’s pharmaceutical sector is dominated by large players (e.g., McKesson, Cardinal Health, Walgreens, CVS), reducing the number of truly vulnerable small firms.
Business & EmploymentPeopleRef: Sec. 2(d) (exclusion of 'self-storage' and other non-drug warehouses); Sec. 2(c) (exclusion of certain licensed facilities)Local governments may lose minor business license or utility fee revenue if some firms reduce operations or restructure to avoid the tax — though this is speculative and likely negligible given the narrow scope of the tax and its low rate.
Local GovernmentLean peopleRef: Sec. 2(g) (tax on 'warehousing and reselling drugs for human use pursuant to a prescription')The bill’s definitions exclude many non-drug warehouse activities (e.g., self-storage, rail freight), but this technical clarity does not meaningfully benefit or burden any group — it simply aligns with existing statutory structure.
Business & EmploymentRef: Sec. 2(d) (exclusions from 'storage warehouse')
Who Is Most Affected
Large pharmaceutical distributors (e.g., McKesson, Cardinal Health, AmerisourceBergen) — which dominate the market — will pay the bulk of the tax. Though they can likely pass some cost to consumers, their profit margins (typically 1–3%) mean this tax represents a meaningful cost increase, potentially affecting pricing strategy and regional distribution decisions.
State and local governments benefit directly from the $25M/year revenue increase, which supports general fund services like public health, education, and transportation. This is a net positive, especially for communities reliant on state funding.
Patients and consumers may see modest price increases if businesses pass through the tax — but given the low rate (0.5%) and competitive nature of drug distribution, pass-through is likely partial (estimated 30–60% in similar cases). Vulnerable populations (e.g., low-income, chronically ill) are most at risk of reduced access if prices rise significantly.
Pharmacy chains and hospital pharmacies that both warehouse and resell prescription drugs (e.g., Walgreens, CVS, Kaiser Permanente pharmacies) may face margin compression if they cannot fully pass the tax to consumers or if contracts with insurers limit price adjustments.
Small, independent pharmacies that rely on third-party distributors (and do not warehouse at scale) are unlikely to be directly taxed, but may indirectly benefit from a more level playing field if large distributors face new costs — though the effect is likely negligible.